MannKind (MNKD) Q3 2024 Earnings Call Transcript

MannKind (MNKD) Q3 2024 Earnings Call Transcript

The Motley Fool Stock Advisor team identified the 10 best stocks for investors, excluding MannKind. MannKind is focusing on developing innovative treatments for diseases like NTM lung disease and IPF. They are also working on inhaled nintedanib for potential use in PPF.

Read More

Did you find this insightful?